Search results
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks via Yahoo Finance· 4 days agoRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes...
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So. | The Motley Fool
The Motley Fool· 2 days agoCRISPR Therapeutics (CRSP 2.24%) closed last week down 8.5% after reporting first-quarter "earnings"...
CRISPR can treat common form of inherited blindness, early data hint
Live Science via Yahoo News· 2 days agoA photo shows two male doctors in surgery garb as one preps a long needle for a procedure. A patient...
How Gene Editing Therapies Could Go Beyond Rare Diseases
Forbes· 1 day agoEarlier this year, a group of scientists in the Netherlands used the gene editing tool CRISPR to...
Gene Editing Breakthrough: CRISPR Improves Vision in Clinical Trial
SciTechDaily· 4 days agoMass Eye and Ear researchers say their findings support continued research and clinical trials of ...
Five Best: Books on Breakthroughs in Biology
The Wall Street Journal· 17 hours agoDoudna and Samuel H. Sternberg (2017) 1. Changing the DNA code in a living organism—to correct a genetic disease, for example—was until recently...
CRISPR Therapeutics’ (CRSP) Neutral Rating Reiterated at Cantor Fitzgerald
ETF DAILY NEWS· 4 days agoCantor Fitzgerald reissued their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday, Benzinga reports ...
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
InvestorPlace· 3 hours agoAll on excitement for its injectable and oral treatments for weight loss, both of which are still in...
World-First Gene Editing Approach Wants To Make Quolls Resistant To Cane Toad Neurotoxins
IFLScience· 4 hours agoIn a world-first application for gene editing technology, Colossal Biosciences is attempting to use ...
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst Downgrade
ETF DAILY NEWS· 6 days agoCRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares dropped 2.1% during trading on Friday after Oppenheimer lowered their price target on the stock from $102.00 ...
